Page last updated: 2024-10-24

cardiac muscle tissue growth involved in heart morphogenesis

Definition

Target type: biologicalprocess

The developmental growth of cardiac muscle tissue that contributes to the shaping of the heart. [GOC:mtg_heart]

Cardiac muscle tissue growth, a fundamental process in heart morphogenesis, involves a complex interplay of signaling pathways, gene expression, and cellular interactions. It begins during embryonic development, where cardiac progenitors commit to a cardiomyocyte fate and proliferate rapidly to form the initial heart tube. As development progresses, this tube undergoes looping and chamber formation, driven by coordinated growth of distinct cardiac regions. This growth is achieved through a combination of cardiomyocyte proliferation, hypertrophy, and migration. Myocyte proliferation is crucial in the early stages, ensuring the expansion of the cardiac cell pool. As the heart matures, hypertrophy, an increase in cell size, becomes more prominent, contributing to the thickening of the heart walls and the formation of distinct chambers. Migration of cardiomyocytes allows for the precise positioning of cells within the developing heart, enabling the formation of specialized structures like valves and trabeculae. This intricate process is tightly regulated by a multitude of signaling pathways, including the Wnt, Notch, and Hedgehog pathways, which play critical roles in cell fate determination, proliferation, and differentiation. Furthermore, numerous transcription factors, such as GATA4, NKX2.5, and MEF2, control the expression of genes involved in heart development. These factors orchestrate the expression of proteins crucial for cardiomyocyte function, including contractile proteins like myosin and actin, and proteins involved in cell adhesion and signaling. The growth of cardiac muscle tissue is also influenced by extracellular matrix proteins, which provide structural support and serve as signaling cues for cardiomyocytes. Throughout this process, the heart undergoes extensive remodeling, with cells continuously interacting with each other and their environment to achieve the final, functional form of the mature organ.'
"

Proteins (1)

ProteinDefinitionTaxonomy
Sphingosine 1-phosphate receptor 1A sphingosine 1-phosphate receptor 1 that is encoded in the genome of human. [PRO:WCB, UniProtKB:P21453]Homo sapiens (human)

Compounds (16)

CompoundDefinitionClassesRoles
fingolimod hydrochloridefingolimod hydrochloride : The hydrochloride salt of 2-amino-2-[2-(4-octylphenyl) ethyl]-1,3-propanediol (fingolimod).

Fingolimod Hydrochloride: A sphingosine-derivative and IMMUNOSUPPRESSIVE AGENT that blocks the migration and homing of LYMPHOCYTES to the CENTRAL NERVOUS SYSTEM through its action on SPHINGOSINE 1-PHOSPHATE RECEPTORS. It is used in the treatment of MULTIPLE SCLEROSIS.
hydrochlorideimmunosuppressive agent;
prodrug;
sphingosine-1-phosphate receptor agonist
fingolimodfingolimod : An aminodiol that consists of propane-1,3-diol having amino and 2-(4-octylphenyl)ethyl substituents at the 2-position. It is a sphingosine 1-phosphate receptor modulator used for the treatment of relapsing-remitting multiple sclerosis. A prodrug, fingolimod is phosphorylated by sphingosine kinase to active metabolite fingolimod-phosphate, a structural analogue of sphingosine 1-phosphate.aminodiol;
primary amino compound
antineoplastic agent;
CB1 receptor antagonist;
immunosuppressive agent;
prodrug;
sphingosine-1-phosphate receptor agonist
sew2871SEW2871: structure in first sourceoxadiazole;
ring assembly
sphingosine 1-phosphatesphingosine 1-phosphate : A phosphosphingolipid that consists of sphingosine having a phospho group attached at position 1

sphingosine 1-phosphate: RN given refers to (R-(R*,S*-(E)))-isomer; RN for cpd without isomeric designation not available 8/89
sphingoid 1-phosphatemouse metabolite;
signalling molecule;
sphingosine-1-phosphate receptor agonist;
T-cell proliferation inhibitor;
vasodilator agent
N-cyclohexyl-5-propyl-3-isoxazolecarboxamidearomatic amide;
heteroarene
N,N-dicyclohexyl-5-propyl-3-isoxazolecarboxamidearomatic amide;
heteroarene
fty 720pfingolimod phosphate : A primary amino compound that is fingolimod in which one on the hydroxy groups has been converted into its dihydrogen phosphate derivative. It is the active metabolite of fingolimod.monoalkyl phosphate;
primary alcohol;
primary amino compound
antineoplastic agent;
immunosuppressive agent;
sphingosine-1-phosphate receptor agonist
jte 013JTE 013: an Edg-5 antagonist

JTE-013 : A semicarbazide derivative that is semicarbazide in which the amino group at position 2 is replaced by a [1,3-dimethyl-4-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridin-6-yl]amino group and the amino group adjacent to the carbonyl is replaced by a (2,6-dichloropyridin-4-yl)amino group. It is a potent S1P2 antagonist (IC50 = 17.6 nM).
chloropyridine;
pyrazolopyridine
anti-asthmatic agent;
anti-inflammatory agent;
antineoplastic agent;
osteogenesis regulator;
pro-angiogenic agent;
sphingosine-1-phosphate receptor 2 antagonist
auy 954AUY 954: an S1P(1) receptor agonist; structure in first source
ponesimodponesimod: structure in first source
fty 720p
VPC 23019VPC 23019 : A secondary carboxamide resulting from the formal condensation of the carboxy group of O-phospho-D-serine with the amino group of m-octylaniline. An analogue of sphingosine-1-phosphate (S1P), it is a potent antagonist for both S1P1 and S1P3 receptors. It can inhibit S1P-induced migration of thyroid cancer cells, ovarian cancer cells, and neural stem cells.

VPC23019: inhibits S1P3 receptor; structure in first source
aromatic amide;
D-serine derivative;
organic phosphate;
phosphoric ester;
secondary carboxamide
sphingosine-1-phosphate receptor 1 antagonist;
sphingosine-1-phosphate receptor 3 antagonist
gw9508GW9508: structure in first sourcearomatic amine
cs-2100
cym-5442oxadiazole;
ring assembly
siponimodsiponimod: S1P receptor modulator